RE: NICE & Data collection for CYP2C1926 Oct 2023 16:20
Yes I know hammer, I was heavily invested at that time.
Everyone, myself included, believed the NICE recommendation would be the door to AIHL being rolled out fully in the NHS and that EU sales would also follow soon after. That was until it dawned on us, Starres was the first who cottoned on, that having been fast tracked by NICE, they had effectively then put us on a slow train to commercialisation. 3 years of data collection before they do another review. Same for this stroke marker test. No chance of a similar rise this time sadly. Hopefully it’ll make it back towards 15p but I’m not sure why it would when sales are so far off and funding is a critical problem already.
A buyout at a budget price imo is the best we can hoped for or else we’re trapped here for years, unless people want to take the loss.
Buy out at 30p and I’d bite your right arm off just now.